Free Trial

Waters (NYSE:WAT) Upgraded to Buy at Wall Street Zen

Waters logo with Medical background

Wall Street Zen upgraded shares of Waters (NYSE:WAT - Free Report) from a hold rating to a buy rating in a report issued on Saturday morning.

Other analysts also recently issued reports about the stock. Barclays dropped their price objective on shares of Waters from $400.00 to $350.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. KeyCorp upgraded Waters from a "sector weight" rating to an "overweight" rating and set a $460.00 price objective for the company in a report on Monday, March 31st. Baird R W raised Waters from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 26th. Bank of America boosted their target price on Waters from $370.00 to $375.00 and gave the stock a "neutral" rating in a research report on Thursday, June 26th. Finally, UBS Group reduced their price target on shares of Waters from $415.00 to $360.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $388.00.

View Our Latest Stock Report on Waters

Waters Price Performance

NYSE:WAT traded down $3.87 during trading hours on Friday, hitting $346.35. 444,744 shares of the company's stock traded hands, compared to its average volume of 472,144. Waters has a 52 week low of $279.24 and a 52 week high of $423.56. The business's fifty day simple moving average is $349.18 and its two-hundred day simple moving average is $364.13. The company has a quick ratio of 1.28, a current ratio of 1.81 and a debt-to-equity ratio of 0.69. The firm has a market cap of $20.61 billion, a P/E ratio of 31.43, a P/E/G ratio of 3.46 and a beta of 1.10.

Waters (NYSE:WAT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical instruments supplier reported $2.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.22 by $0.03. The firm had revenue of $661.71 million during the quarter, compared to the consensus estimate of $655.50 million. Waters had a return on equity of 41.70% and a net margin of 22.02%. The company's revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter last year, the company posted $2.21 EPS. On average, research analysts anticipate that Waters will post 12.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Waters

A number of hedge funds have recently modified their holdings of WAT. Lederer & Associates Investment Counsel CA increased its holdings in Waters by 1.0% during the 1st quarter. Lederer & Associates Investment Counsel CA now owns 3,155 shares of the medical instruments supplier's stock valued at $1,163,000 after purchasing an additional 30 shares during the period. Integrated Wealth Concepts LLC grew its position in shares of Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier's stock worth $386,000 after buying an additional 30 shares during the last quarter. FourThought Financial Partners LLC increased its stake in shares of Waters by 5.1% during the first quarter. FourThought Financial Partners LLC now owns 658 shares of the medical instruments supplier's stock valued at $243,000 after buying an additional 32 shares during the period. Larson Financial Group LLC raised its holdings in shares of Waters by 6.8% during the fourth quarter. Larson Financial Group LLC now owns 537 shares of the medical instruments supplier's stock valued at $199,000 after acquiring an additional 34 shares in the last quarter. Finally, Benjamin Edwards Inc. lifted its stake in Waters by 4.8% in the fourth quarter. Benjamin Edwards Inc. now owns 744 shares of the medical instruments supplier's stock worth $276,000 after acquiring an additional 34 shares during the period. Hedge funds and other institutional investors own 94.01% of the company's stock.

About Waters

(Get Free Report)

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Further Reading

Analyst Recommendations for Waters (NYSE:WAT)

Should You Invest $1,000 in Waters Right Now?

Before you consider Waters, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.

While Waters currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines